Objective. Patients with hyperuricemia or gout often have metabolic syndrome. Few prospective studies have examined the risk of incident diabetes mellitus (DM) in patients with gout, and there are no data to indicate whether the risk of DM in gout differs by sex. Therefore, this cohort study was undertaken to examine the overall and sex-specific incidence rates of DM in patients with gout.
Gout is a common inflammatory arthritis caused by hyperuricemia (1) . In 2007, nearly 8.3 million Americans had gout, and the prevalence of gout and hyperuricemia continues to increase (2) . Cross-sectional studies have shown that gout and hyperuricemia are associated with metabolic syndrome, generally defined as a cluster of cardiovascular risk factors including abdominal obesity, hypertension, dyslipidemia, and insulin resistance (3, 4) . A recent Taiwanese study found that gout and type 2 diabetes mellitus (DM) share common genetic risk alleles (5) . Although growing evidence supports the notion that hyperuricemia is independently associated with a greater future risk of developing metabolic syndrome and DM (6) (7) (8) (9) , limited longitudinal data exist on the risk of incident DM in patients with gout. One prospective cohort study of men with a high cardiovascular risk profile (no analyses were performed in women) found that gout was associated with a higher risk of incident DM, as compared to that in subjects without gout (10) .
Since gout and hyperuricemia are more common in men than in women, most epidemiologic studies have focused on men. However, results of several previous studies have indicated that the risk of coronary heart disease and hypertension associated with hyperuricemia or gout was greater in women compared to men (11) (12) (13) . Although it is not well understood, the different impact of gout or hyperuricemia on cardiovascular risk by sex is thought to be related to differences in serum uric acid levels and distribution of comorbidities between the sexes (11, 12, 14, 15) . In addition, uric acid was a strong independent risk factor for DM in women but not in men in a previous population-based cohort study (16) . To date, no published study has provided prospective data with regard to whether the risk of incident DM or metabolic syndrome associated with gout is different between women and men.
We therefore studied a large longitudinal cohort from a US health care utilization database, with the following aims: 1) to estimate the overall and sex-specific incidence rates of DM among patients with gout and those without gout, 2) to assess the risk of incident DM among patients with gout compared to those without gout, and 3) to test whether the risk of incident DM associated with gout differs by sex.
PATIENTS AND METHODS
Data source. We conducted a cohort study using the claims data from United HealthCare, a large commercial health insurance plan in the US, for the period January 1, 2003 to December 31, 2012. This database contains longitudinal claims information, including medical diagnoses, procedures, hospitalizations, physician visits, and pharmacy dispensing records, on more than 13 million fully insured subscribers with medical and pharmacy coverage at any particular time point across the US. Results of outpatient laboratory tests, including measurements of the hemoglobin A 1c (HbA 1c ) and uric acid levels, were available for a subset of beneficiaries. Personal identifiers were removed from the data set before the analysis, to protect subject confidentiality. Patient informed consent was therefore not required. The study protocol was approved by the Institutional Review Board of Brigham and Women's Hospital.
Study cohort. Eligible patients in the gout group consisted of subjects ages 40 years and older who had at least 2 visits coded with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 274.0X, 274.8X, and 274.9 for gout. The index date for the gout group was the date of the first dispensing of a gout-related drug (i.e., allopurinol, febuxostat, colchicine, probenecid, selective and nonselective nonsteroidal antiinflammatory drugs [NSAIDs] , and systemic and intraarticular steroids) after at least 365 days of continuous health plan eligibility; thus, all patients in the gout cohort were required to have been diagnosed as having gout on at least 2 physician visits and to have filled at least 1 prescription for a gout-related drug by the time of the index date. We excluded nursing home residents or patients who had been given a diagnosis of malignancy or who had received chemotherapy in the 365-day period prior to the index date. To ensure that only incident cases of DM were included in all cohorts, we excluded patients with an existing diagnosis of DM or whose records showed any dispensings of an antidiabetic drug or use of an insulin pump in the 365-day period prior to the index date.
For comparison, we selected 2 nongout groups of subjects ages 40 years and older. The first comparator group, described as the osteoarthritis (OA) group, consisted of patients who had at least 2 visits coded with the ICD-9 code 715.XX for OA, a chronic arthritis characterized by less systemic inflammation. This group was chosen as the primary comparator group, because patients with OA have a pattern of health care utilization (e.g., frequency of visits to physicians) and baseline characteristics, such as physical activity and obesity, similar to that in patients with gout. The index date for the OA group began at the first receipt of opioids or selective or nonselective NSAIDs after at least 2 physician visits for OA. The aforementioned exclusion criteria were then applied. Patients with OA were not included if they had also been diagnosed as having gout or if they had a history of use of allopurinol, febuxostat, colchicine, or probenecid in the 365-day period prior to or on the index date. The OA group was then matched to the gout group for age, sex, and index date, in a ratio of 3:1.
The second comparator group, described herein as the nongout group, consisted of patients who did not have a diagnosis of gout at baseline and who had a record of at least 2 physician visits after at least 12 months of continuous health plan eligibility. The index date for the nongout patients began at the first receipt of any prescription drugs after at least 2 physician visits. Patients were included in the nongout group if they had not been treated with allopurinol, febuxostat, colchicine, or probenecid in the 365-day period prior to or on the index date. Patients in the nongout group were then matched to the gout patients for age, sex, and index date, in a ratio of 3:1.
Patients in both comparator groups were followed up from the index date to the first occurrence of any of the following censoring events: development of DM, development of gout (for both the OA and the nongout groups), insurance disenrollment, end of study period, or death.
Definition of outcome. Incident DM was defined based on a diagnosis of DM and at least one recorded dispensing of an antidiabetic drug (a list of the specific drugs is available upon request from the corresponding author). The date of the first antidiabetic drug dispensing was used as the date of outcome occurrence.
Covariates. Patients' baseline variables potentially related to gout or the development of DM were examined using data from the 365 days before the index date. These variables included demographic factors (age, sex, and region of residence), comorbidities (hypertension, stroke, coronary heart disease, heart failure, chronic kidney disease, liver disease, sleep apnea, hyperlipidemia, alcoholism, smoking, and obe- 
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a comorbidity score that combined conditions included in both the Charlson Index and the Elixhauser system based on the ICD-9-CM codes (17) . The comorbidity score is a summative score, based on 20 major medical conditions such as metastatic cancer, congestive heart failure, dementia, renal failure, weight loss, hemiplegia, pulmonary disease, and liver disease. The score ranges from Ϫ2 to 26. In a subgroup of the study cohort, outpatient laboratory test results, such as levels of HbA 1c , acute-phase reactants, and uric acid, were also examined. Statistical analysis. We compared the baseline characteristics between the gout group and OA group, matched for age, sex, and index date. We estimated the overall and sex-specific incidence rates of DM, with 95% confidence intervals (95% CIs), in both groups. The overall and sexspecific rate ratios, with 95% CIs, were estimated by dividing the incidence rates of DM among gout patients by the incidence rates of DM among OA patients (18) .
We tested for an interaction between gout and sex by including the product term in a multivariable Cox proportional hazards model. Using this model, we found a statistically significant interaction between gout and sex (P ϭ 0.0009). We therefore used sex-stratified multivariable Cox models, which were adjusted for various potential confounders, to compare the risk of incident DM among gout patients to that in patients with OA (19) . Partially adjusted, sex-stratified Cox models included age, comorbidity score, and number of prescription drugs. Fully adjusted Cox models included age, comorbidities, medications, and health care utilization factors (as listed in Table 1 ). All analyses were then repeated for the comparison between the gout and nongout groups.
Kaplan-Meier curves were plotted for the cumulative incidence of DM in the gout group and matched OA group, stratified by sex. A sensitivity analysis adjusted for baseline HbA 1c levels was conducted among patients for whom we had a baseline HbA 1c measurement available. In addition, a sensitivity analysis adjusted for elevated levels of acute-phase reactants at baseline was conducted among patients for whom we had a baseline acute-phase reactant measurement available. We also used stratified Cox proportional hazards regression models to assess whether the impact of gout on the risk of DM differed by steroid use at baseline and by cumulative dose of steroids during the 365-day baseline period. The proportional hazards assumption was assessed by testing the significance of the interaction term between exposure (i.e., gout or OA) and time, and was not violated in any models (20) . All analyses were done using SAS statistical software (version 9.3; SAS Institute).
RESULTS
Cohort selection. There were initially 289,684 patients with at least one gout diagnosis and 1,822,117 with at least one OA diagnosis after a 365-day enrollment period. After applying the inclusion and exclusion criteria, we selected 3 OA patients for each gout patient, matched for age, sex, and index date. Our final study cohort included 54,075 patients with gout and 162,225 patients with OA. Figure 1 displays the study cohort selection process. The mean Ϯ SD followup time was 1.94 Ϯ 1.72 years for patients with gout and 1.91 Ϯ 1.72 years for patients with OA.
For the comparison between the gout group and the nongout group, 66,119 patients with gout were matched for age, sex, and index date to nongout patients in a ratio of 1:3 (baseline characteristics of the nongout group are available upon request from the corresponding author). The mean Ϯ SD followup time was 1.86 Ϯ 1.68 years for patients with gout and 1.87 Ϯ 1.74 years for nongout patients.
Patient characteristics. Baseline characteristics of the age-, sex-, and index date-matched gout and OA groups were compared ( Table 1 ). The mean age in both cohorts was 56.2 years, and men comprised 84.8% of the patients in each group. Patients with gout experienced a greater frequency of hypertension, heart failure, coronary heart disease, chronic kidney disease, obesity, and hyperlipidemia compared to the OA group. Use of drugs, such as steroids, NSAIDs, and diuretics, and emergency room visits were more common in gout patients than in OA patients. During the 365-day baseline period, HbA 1c tests were ordered for 9.8% of gout patients and 7.0% of OA patients.
Among the patients with gout, women had more comorbidities, such as hypertension, obesity, chronic kidney disease, and heart failure, than men. Moreover, women were treated with steroids and utilized the health care system more frequently than men (details available upon request from the corresponding author). Among the gout patients at baseline, 60% had received at least one prescription for either allopurinol or febuxostat.
Risk of incident DM in gout compared to OA. The incidence rate of DM was 1.91 per 100 person-years in gout patients and 1.12 per 100 person-years in OA patients ( Table 2 ). The age-, sex-, and index datematched rate ratio of incident DM was 1.71 (95% CI 1.62-1.81) in the overall gout group compared to the OA group, but, importantly the rate ratio was higher in women (rate ratio 2.42, 95% CI 2.09-2.81) than in men (rate ratio 1.62, 95% CI 1.53-1.72). Table 3 summarizes the results from various multivariable Cox regression analyses comparing the risk of incident DM between the gout group and the OA group. After adjustments for age, comorbidities, medications, and health care utilization intensity in the models, the risk of DM associated with gout was increased in both men and women, with a greater hazard ratio in women (hazard ratio 1.78, 95% CI 1.51-2.09) compared to men (hazard ratio 1.41, 95% CI 1.33-1.50). Kaplan-Meier curves demonstrated that the cumulative incidence of DM was higher in the age-, sex-, and index date-matched gout group compared to the OA group (results available upon request from the corresponding author).
Risk of incident DM in gout compared to nongout. The incidence rate of DM was 1.83 per 100 person-years in gout patients and 0.98 per 100 personyears in nongout patients. The age-, sex-, and index date-matched rate ratio was 1.88 (95% CI 1.78-1.98) in the gout group as compared to the nongout group. Similar to the comparison between gout and OA, the rate ratio was higher in women (rate ratio 2.74, 95% CI 2.35-3.19) than in men (rate ratio 1.79, 95% CI 1.69-1.89). After adjustments for age, comorbidities, medications, and health care utilization intensity, the risk of DM associated with gout was increased in both men and women, with a greater hazard ratio in women (hazard ratio 1.58, 95% CI 1.29-1.94) compared to men (hazard ratio 1.27, 95% CI 1.18-1.36).
Sensitivity analyses. Among the subgroup of patients with a baseline HbA 1c measurement available, a diagnosis of gout, as compared to a diagnosis of OA, appeared to be associated with an increased risk of incident DM in both women (hazard ratio 1.71, 95% CI 0.85-3.43) and men (hazard ratio 1.37, 95% CI 1.06-1.76) after adjustment for age and baseline HbA 1c level. Among the subgroup of patients with a baseline acutephase reactant measurement available, gout was still associated with an increased risk of incident DM in both women (hazard ratio 2.66, 95% CI, 1.44-4.92) and men (hazard ratio 1.54, 95% CI 1.19-1.98), as compared to that in OA patients, after adjustment for age and baseline acute-phase reactant levels.
The risk of incident DM associated with gout was consistently increased in both women and men, regardless of whether patients had been receiving steroids at baseline and regardless of the cumulative dose of prednisone (or equivalent) ( Table 4 ). The risk of incident DM associated with gout was increased in women who had a higher cumulative prednisone (or equivalent) dose during the 365-day baseline period, with a hazard ratio * The study cohorts were age-, sex-, and index date-matched. 95% CI ϭ 95% confidence interval. † Incidence rate is per 100 person-years. Table 3 . Risk of incident diabetes mellitus in patients with gout compared to those with osteoarthritis of 2.29 (95% CI 1.40-3.74) in women in the highest tertile (cumulative dose Ն325 mg). In men with the highest cumulative prednisone (or equivalent) dose (cumulative dose Ն316 mg), the hazard ratio of incident DM associated with gout was 1.27 (95% CI 1.01-1.60).
DISCUSSION
In this large cohort study using data from a nationwide US commercial insurer, nearly 2% of the patients with gout developed type 2 DM during a mean followup of 1.9 years. Gout was associated with an increased risk of developing DM after the analyses were controlled for potential confounders, including age, comorbidities, medications, and health care use patterns. This result is consistent with the findings from a previous study based on male patients in the Multiple Risk Factor Intervention Trial (10) . Furthermore, the results of the present study draw attention to a greater impact of gout on the risk of incident DM in women compared to men. This study also showed that women with gout had more comorbid conditions and utilized prescription drugs and the health care system more often than men. Our results remained robust in the analyses comparing gout and nongout patients, as well as in the sensitivity analyses adjusted for baseline HbA 1c levels and stratified by the baseline use of steroids.
The reason that women with gout have a higher risk of DM than men with gout is unclear. A prior study showed a greater impact of hyperuricemia on the risk of metabolic syndrome in women compared to men (8) . Similarly, a number of previous studies demonstrated that the effects of gout on cardiovascular risk were sex-specific (11) (12) (13) . In a Canadian population-based study, women with gout had a relative risk of 1.39 for acute myocardial infarction, while men with gout had a relative risk of 1.11, as compared to those without gout (11) . Women with gout were noted to have a higher mean serum uric acid concentration and a lower mean urinary excretion of uric acid than did men with gout in a Spanish cohort of men and postmenopausal women 14). It has been suggested that these differences in uric acid levels and urate metabolism between the sexes might explain the more pronounced cardiovascular risks associated with gout in women than in men (14, 15) . In the present study, there were substantial differences in the baseline characteristics between men and women with gout. The mean age was higher in women than in men, and the proportion of patients with obesity, smoking, and recent steroid use was much higher in women with gout compared to men with gout. The impact of gout on the risk of DM remained larger in women, even after the analyses were adjusted for these differences in baseline characteristics. However, it is possible that the degree of confounding by unmeasured variables, such as physical activity, diet pattern, and body mass index, on the association between gout and DM is larger in women than in men.
Several prospective studies showed that hyperuricemia preceded the development of hyperinsulinemia, suggesting that hyperuricemia may be an independent risk factor for hyperinsulinemia or DM (21, 22) . Furthermore, markers of systemic inflammation, such as the levels of C-reactive protein, interleukin-6, and soluble adhesion molecules, appear to play a role in the development of type 2 DM (23) (24) (25) (26) . Thus, systemic inflammation caused by gout may contribute to insulin resistance at the onset of DM.
Another hypothesis generated by the present study posits a potential role for urate-lowering therapy in reducing the risk of incident DM among patients with chronic gout. No published studies have presented evidence on the effect of urate-lowering therapy on the risk of DM. However, a small cohort study of 12 patients with end-stage renal disease showed a significant decrease in the serum levels of low-density lipoprotein cholesterol and triglycerides after treatment with allopurinol at 300 mg twice daily for 3 months (27) . Furthermore, a potential benefit of allopurinol, in terms of its effects on hypertension, cardiovascular morbidity, and mortality, has been suggested (28, 29) . Several strengths of this study are noteworthy. First, we examined a large cohort of patients with gout and patients with OA in a population that is representative of the US commercially insured population. Second, to minimize surveillance bias, we selected a group of patients with OA, a chronic noninflammatory medical condition requiring pharmacologic treatment, for comparison. In addition, we performed an additional comparison between gout patients and nongout patients, which yielded similar findings, showing an increased risk of incident DM associated with gout. Third, we included a large number of women in the cohort, and the results revealed an interaction between gout and sex in relation to the risk of incident DM. Fourth, unlike most claims data sources, we had actual laboratory results (e.g., HbA 1c and uric acid levels) available in a subgroup of patients. Sensitivity analyses in this subgroup of patients with baseline HbA 1c levels available showed a consistently increased risk of incident DM in patients with gout. Finally, we also performed additional analyses to examine the effect of gout stratified by the use and cumulative dose of systemic steroids.
There are limitations to this study. First, we mainly relied on the claims data to select patients with gout, patients with OA, or nongout patients and to identify their comorbidities, raising the possibility for exposure and outcome misclassification bias. However, we required all of the patients in the 2 primary study cohorts to have been prescribed at least one gout-or OA-related drug in addition to having at least 2 visits coded with a diagnosis of gout or OA, to minimize the exposure misclassification. For the main outcome, to maximize the specificity, we identified incident DM cases based on a diagnosis code and a dispensing for antidiabetic drugs. Thus, patients with diet-controlled DM were not included. This may have resulted in an underestimation of the incidence rate of DM in this study, as a prior study (10) that defined DM based on a fasting glucose level or use of antidiabetic medication found higher incidence rates.
Second, even though we adjusted for more than 40 variables in the multivariable Cox proportional hazards models, this study may be subject to residual confounding by family history of DM, physical activity, obesity, menopausal status among women, and diet.
Third, the association between gout and incident DM noted in this study may not be causal. However, our findings are consistent with those of a prior study (10) in which the reported relative risk of DM was 1.34 (95% CI 1.09-1.64) in men with gout, after adjustments for age, body mass index, family history of DM, smoking, alcohol use, dietary factors, and presence of individual components of metabolic syndrome.
Finally, the mean followup period was Ͻ2 years. Nevertheless, we expect that the risk of DM associated with gout would be similarly increased over time, as the proportional hazards assumption was not violated in any of the models.
In conclusion, gout remained significantly associated with an increased risk of developing DM after adjustment for potential confounders, and the impact of gout on the risk of incident DM was higher among women than among men. This study highlights the importance of patient education for lifestyle modification, as well as careful monitoring of diabetic risk factors, to reduce the risk of diabetes or metabolic syndrome among patients with gout, particularly women with gout. Because hyperuricemia and systemic inflammation may have a role in the causal pathway to type 2 DM, future research is needed to examine the role of aggressive gout management, including urate-lowering therapy, in possibly attenuating the risk of DM.
